Brought to you by 
Concordia buys Amdipharm for $3.5bn in up-front and earn-out payments
17 Sep 2020
Executive Summary
Concordia Healthcare Corp. acquired private specialty pharmaco Amdipharm Mercury Ltd. (AMCo) for $3.5bn: $1.2bn in cash, 8.5mm Concordia shares (valued at $643mm), the assumption of $1.4bn in AMCo debt, and a $220mm cash earn-out based on performance and due in Q4 2016.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Concordia buys Amdipharm for $3.5bn in up-front and earn-out payments
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice